Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol (NQF 0074)

eMeasure Name Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol eMeasure Id B39A6DC1-02A3-4583-8E63-5BEF0641AAF1
Version number 1 eMeasure Set Id 63A24CBA-F9E7-4A52-93BE-E987B7B4E422
Available Date No information Measurement Period January 1, 20xx through December 31, 20xx
Measure Steward American Medical Association - Physician Consortium for Performance Improvement
Endorsed by National Quality Forum
Description Percentage of patients aged 18 years and older with a diagnosis of CAD who were prescribed a lipid-lowering therapy (based on current ACC/AHA guidelines)
Copyright
© 2010 American Medical Association. All Rights Reserved
Measure scoring Proportion
Measure type Process
Stratification
None
Risk Adjustment
None
Data Aggregation
Rationale
Studies have demonstrated that active treatment with lipid-lowering therapy is associated with stabilization and regression of coronary atherosclerotic plaques and decreased incidence of clinical events. Recent clinical trials have further documented that LDL-lowering agents can decrease the risk of adverse ischemic events in patients with established CAD.
Clinical Recommendation Statement
The LDL-C treatment goal is <100 mg/dl. Persons with established coronary heart disease (CHD) who have a baseline LDL-C >=130 mg/dl should be started on a cholesterol-lowering drug simultaneously with therapeutic lifestyle changes and control of nonlipid risk factors (National Cholesterol Education Program [NCEP]).
Improvement notation
Higher score indicates better quality
Measurement duration
12 month(s)
Reference
National Heart, Lung, and Blood Institute. National Cholesterol Education Program (NCEP). Third report of the NCEP on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). NIH Publication No. 01-3305.2001.
Definition
Initial Patient Population(s): 
Patient Age:  Patients aged 18 years and older at the beginning of the measurement period.
Diagnosis Active:  Patient has a documented diagnosis of coronary artery disease.
Encounter:  At least 2 visits with the physician, physician's assistant, or nurse practitioner during the measurement period.
Definition
Denominator(s): All patients aged 18 years and older with a diagnosis of coronary artery disease.
Definition
Denominator Exclusion(s): N/A
Definition
Numerator(s): Patients who were prescribed lipid-lowering therapy.
Definition
Denominator Exception(s): Documentation of medical reason(s) for not prescribing lipid-lowering therapy (eg, clinical contraindication, drug allergy, drug interaction, drug intolerance, other medical reason(s)).  Documentation of patient reason(s) for not prescribing lipid-lowering therapy (eg, patient declined).  Documentation of system reason(s) for not prescribing lipid-lowering therapy.
Guidance
Supplemental Data Elements
Report "Patient Characteristic: Gender" using "Gender HL7 Value Set (2.16.840.1.113883.1.11.1)"; Report "Patient Characteristic: Race" using "Race CDC Value Set (2.16.840.1.114222.4.11.836)"; Report "Patient Characteristic: Ethnicity" using "Ethnicity CDC Value Set (2.16.840.1.114222.4.11.837)"; Report "Patient Characteristic: Payer" using "Payer Source of Payment Typology Value Set (2.16.840.1.113883.3.221.5)".

Table of Contents


Population criteria

Data criteria (QDM Data Elements)

Supplemental Data Elements




Measure set CLINICAL QUALITY MEASURE SET 2011-2012